The Next 150 Raises $2 Million USD to Scale Climate Solutions in Emerging Markets

GENÈVE, SWITZERLAND and MEXICO CITY, MEXICO / March 16, 2023 / The Next 150, a climate-forward venture operator, has announced its official launch with offices in Switzerland and Mexico. The company is focused on scaling climate solutions in emerging markets to support the transition to a low-carbon economy.

Related Image

The Next 150 Logo
The Next 150 Company logo uses a symbol of movement, for transformation of key ideas into concrete plans and actions, with an interpolation of elements from one key moment into another.

The Next 150, founded by Patrick Atanasije Pineda and Constantin Ekierman, has raised $2 million in seed capital from Kemexon SA, with additional capital earmarked for investment to develop, scale and industrialize climate technologies, such as biochar production from waste biomass and its incorporation in soil and construction materials.

The Kemexon group is a global trading and supply chain logistics company with over 20 years of activity across a range of commodity products. “We look forward to exploring opportunities and uncovering synergies with our existing interests in biomass markets, in support of the energy transition and a path to decarbonization.” – Alexia Bricout, co-CEO of Kemexon

The Intergovernmental Panel on Climate Change, IPCC, estimates that by 2050, we will need to remove 3-12 billion tons of CO2 from the air every year in order to meet the Paris Agreement goals. The Next 150 is developing high-quality emissions removal projects with a boots-on-the-ground approach.

About The Next 150

Ekierman and Pineda bring a unique set of experiences that has spanned executing over $350M USD in carbon markets, to building ISO-certified agricultural production and processing facilities. These projects and investments include inking a deal with a UEFA Champions League team for their carbon abatement goals, and the origination and structuring of a large-scale, high-tech biochar project in Latam, with an installed capacity of 50,000MT of biomass waste.

The Next 150’s Mexico office is led by Luisa Marin, Country Director, bringing 25 years of experience from the international development sector having managed multi-stakeholder initiatives at The Nature Conservancy and Conservation International. The office has an experienced technical team headed by Benjamin Pozos, Technical Director, a lead verifier in carbon projects in Mexico under ISO 14064:3 and an industry veteran.

According to the International Monetary Fund, private sustainable finance in emerging markets and developing economies reached a record of $250 billion last year. The Next 150 will capitalize on the growth of green finance and carbon markets, utilizing its in-house operational experience to invest and operate in the global south, ensuring that local projects make a global impact.

Contact Information

Rafael Gamboa
Director of Communications
+52 55 3227 3531

SOURCE: The Next 150 SA de CV

ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care Units

ART MEDICAL Ltd. is pleased to announce its collaboration with Teva Israel. Under the terms of the agreement, Teva Israel will market and distribute ART MEDICAL’s ground-breaking smART+ Platform in Israel’s intensive care units.

NETANYA, ISRAEL / ACCESSWIRE / March 16, 2023 / The smART+ Platform is a robotic-assisted technology that aims to reduce complications related to feeding tube malposition, malnutrition, Ventilator-Associated Pneumonia (VAP), and Acute Kidney Injury (AKI). By delivering transformative new-to-the-world data, the smART+ Platform enables medical staff to take a comprehensive approach to critical care, make informed decisions and improve patient outcomes.

Related Image

Current related practices in intensive care units rely mostly on manual work and cumbersome procedures. ICU patients are routinely subjected to the risks of malnutrition, tube malposition, and pneumonia. Without technological solutions, nutrition treatment leads to inaccuracies, increased workloads on care teams, and generic nutrition plans that are neither personalized nor updated in real time. The smART+ Platform uses a proprietary sensor-based feeding tube, continuous metabolic assessment, and algorithms, to provide real-time monitoring and closed-loop feedback, resulting in better and personalized care for critically ill patients.

ART MEDICAL’s Founder and CEO, Liron Elia, says, “Our goal, at ART MEDICAL, is to improve patient outcomes through cutting-edge technology. By integrating real-time data, monitoring, and control mechanisms, the smART+ Platform addresses several of the greatest clinical challenges of intensive care units. This powerful combination provides a comprehensive and innovative nutritional therapy practice as well as optimized care delivery. We are thrilled to partner with Teva Israel to bring our technology to critically ill patients and clinical teams in ICUs.”

Yossi Ofek, GM-Teva Israel, SVP; Cluster Head – Middle East, Africa & Ukraine says:

“Teva Israel continually strives to offer innovative and safe treatment options – both in the community and in hospitals – in order to improve the lives and health of patients.

“The innovative development of an Israeli company, ART MEDICAL, is intended to ensure that patients in intensive care units receive the most advanced treatment offered today that can minimize complications related to hospitalization and reduce length of stay.”

About Teva Israel:

‘Teva Israel’ is the home-based marketing arm of Teva Pharmaceutical Industries Ltd, where it has been working to improve the lives and health of patients, for over 120 years, through high-quality and affordable medicines.

As a leading player in the local health market and particularly in the generics and OTC markets, Teva Israel provides unique services in Israel to Israeli residents, through its logistics company SLE – and markets a wide variety of medicines and products: from original innovative medicines and generic medicines, through medical equipment and devices for hospitals, to over the counter (OTC) medicines and baby milk formula.

Teva Israel is also an innovation incubator for Teva Global and established, in collaboration with Philips, Sanara Ventures, a platform for investments in start-up companies in the fields of digital medicine and medical devices. In Israel, one of every four prescriptions is for a Teva drug, while the annual savings that the company’s generic drugs bring to the Israeli healthcare system is estimated at about one and a half billion shekels, per year.


ART MEDICAL is on a mission to save lives through technological innovations and redefine the future of critical care. Our goal is to see ICU patients get better faster with the help of real-time nutrition management. Visit or follow us on LinkedIn for more information.

Forward-Looking Statements of ART MEDICAL

ART MEDICAL developed the smART+™ Platform as a holistic approach for the next-generation ICU, featuring an ecosystem of sensor-based tools, software, and algorithms. smART+ is designed to prevent ICU-acquired complications. The smART+ Platform aims to reduce length of ventilation days and length of stay that are attributed to malnutrition, VAP, and other secondary infections and complications, ultimately providing better care, and dramatically reducing healthcare costs.



Contact Information

Ori Braun
SVP Business Development


Sustainalytics Upgrades INNIO Group’s ESG Risk Rating From Low to Negligible Risk, Ranking INNIO Number 1 Worldwide Among Industry Peers

Sustainalytics ESG rating places INNIO in top 1 percentile of all industry peers and in top 2 percentile of companies rated by Sustainalytics on a global level. • INNIO receives Sustainalytics’ ESG risk score of 9.8, improving by 11% compared to 2022. • INNIO also receives Sustainalytics’ 2023 “ESG Industry Top rated” and “ESG Regional Top Rated” badges.

JENBACH, AUSTRIA / ACCESSWIRE / March 16, 2023 / INNIO today announced that Sustainalytics has upgraded INNIO Group’s ESG risk score to 9.8, an improvement of 1.2 points year-over-year, and has upgraded the company’s risk rating from low to negligible. The rating from Sustainalytics, a global leader in ESG research, ratings, and data, reinforces INNIO’s number 1 position compared to peers across both Machinery and Industrial Machinery worldwide.

“Improving our Sustainalytics rating is not only a reflection of our dedication to environmental, social and governance responsibility, it is also a testament to the hard work and collaboration of our talented team,” said Dr. Olaf Berlien, president and CEO of INNIO. “We will continue to prioritize sustainable practices and innovation for the benefit of our business, our stakeholders, and our planet.”

The Sustainalytics risk rating improvement is a vital recognition for INNIO and an indicator of the company’s commitment to sustainable policies and programs. The risk rating focus includes health and safety, environment and carbon management, human capital, procurement practices and circularity. The rating upgrade signals that INNIO’s initiatives and actions to reduce its environmental impact, promote social equity, and ensure good governance are demonstrating positive results. It also underlines INNIO’s commitment to transparency and accountability, which are important factors in building trust and credibility with stakeholders, including customers, suppliers, investors, and employees.

Learn more about the ESG Risk Ratings.

About Sustainalytics

Sustainalytics is a global leader in ESG research, ratings, and data, serving the world’s leading institutional investors and corporations. Sustainalytics works with hundreds of the world’s leading asset managers and pension funds who incorporate ESG and corporate governance information and assessments into their investment processes. For more information regarding Sustainalytics ESG rating, please visit

About INNIO 

INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.

INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 4,000 experts provides life-cycle support to the more than 55,000 delivered engines globally through a service network in more than 100 countries.

INNIO’s improved ESG Risk Rating again secures the number one position across more than 500 companies globally in the machinery industry assessed by Sustainalytics.

For more information, visit INNIO’s website at Follow INNIO on Twitter and LinkedIn.

Contact Information

Susanne Reichelt
INNIO Media Relations
+43 664 80833 2382

Related Image


De Novo Dairy Announces Rebrand and Headquarters Move to London

De Novo Dairy, a leading precision fermentation company, announced today its official rebrand to De Novo Foodlabs. The new name reflects the company’s expanded focus on creating sustainable nutrients that improve the health of people and the planet through precision fermentation and other technologies.

LONDON, ENGLAND / ACCESSWIRE / March 16, 2023 / De Novo Dairy, a leading precision fermentation company, announced today its official rebrand to De Novo Foodlabs. The new name reflects the company’s expanded focus on creating sustainable nutrients that improve the health of people and the planet through precision fermentation and other technologies.

Related image

De Novo Foodlabs Rebrand
De Novo Foodlabs new logo and brand


De Novo Foodlabs’ proprietary precision fermentation platform enables the creation of high-quality and nutrient-rich ingredients from non-animal sources. The company’s technology is at the forefront of a global movement towards a more sustainable and ethical food system.

With its headquarters move to London in quarter four of 2023, De Novo Foodlabs will be at the heart of Europe’s vibrant foodtech community. This strategic relocation will allow the company to strengthen its partnerships with leading food and beverage companies, research institutions and investors.

“We are thrilled to be rebranding to De Novo Foodlabs and relocating our headquarters to London. This is a significant milestone in our company’s journey,” said CEO Jean Louwrens. “Our new name and broader focus reflect our commitment to creating a better food system for everyone, and we are excited to be at the forefront of this movement.”

The rebranding of De Novo Dairy to De Novo Foodlabs represents a significant shift for the company as it continues to lead the way in the precision fermentation space. With its innovative technology, De Novo Foodlabs is set to make a significant impact on the global food system by creating sustainable, nutritious and commercially attractive ingredients.

For more information on De Novo Foodlabs and its precision fermentation technology, visit

Contact Information

Samantha Ritchie
Media Liaison, Little Biggies

SOURCE: De Novo Foodlabs

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Growing body of data supports Ampligen’s potential as both a prophylactic and an early-onset therapy against human Ebola virus disease outbreaks

OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced a late-breaking presentation at the 36th International Conference on Antiviral Research (ICAR) detailing Ampligen’s mechanism of action in the treatment of Ebola virus disease (EVD).

The presentation was given by Angela Corona, PhD, Department of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy, and one of the published authors of a recent manuscript titled “Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action.” Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of EVD in Central Africa capable of reaching epidemic status. Highlights of the recently published Ampligen data that was presented include:

  • As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
  • Ampligen appears to inactivate the EBOV lethal factor (EBOV VP35), which is believed to be responsible, in part, for the high mortality rate observed in humans, by acting as a “competitive decoy.” VP35 is understood to sequester the dsRNA produced by EBOV during its replication, which inhibits the normal innate immune responses to viral infection.
  • Ampligen protected mice from a lethal challenge by mouse adapted EBOV-Zaire and its associated weight loss.
  • The 6 mg/kg doses, frequently used in AIM’s clinical trials, used in mouse model is easily achievable and well tolerated in humans.
  • Overall, the data suggest Ampligen’s potential as a viable candidate to protect against exposure to EBOV.

The corresponding slides from the presentation at ICAR are now available on the Company’s website ( on the “Events and Presentations” page.

AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease. Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease. Those animal studies are indicative of the drug’s high potential for efficacy. The analysis presented at ICAR now provides a clear understanding of why Ampligen is achieving such a high level of efficacy in these animal models, signaling its potential as a human therapy.”

Ampligen has been granted Orphan Drug status for Ebola virus disease by the European Medicines Agency and the FDA. Ampligen is not currently approved for the prevention or treatment of EVD.

The Company intends to file Investigational New Drug applications to study the use of Ampligen (1) as an early onset therapy for the treatment of EBOV, and (2) for the prevention of Ebola virus reactivation. Ultimately, the Company’s goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

About the International Society for Antiviral Research (ISAR)

The International Society for Antiviral Research (ISAR) is an internationally recognized organization for scientists involved in basic, applied, and clinical aspects of antiviral research. The Society main event is the annual International Conference on Antiviral Research (ICAR), a truly interdisciplinary meeting which attracts the interest of chemists, biologists, and clinicians.

About Ampligen

Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country. Ampligen is being used to treat pancreatic cancer patients in an Early Access Program approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center. Additionally, Ampligen is also approved in Argentina for the treatment of severe chronic fatigue syndrome and is currently being evaluated in SARS-CoV-2/COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, an investigational new drug called Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being investigated for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit and connect with the Company on Twitter, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The clinical study and other matters discussed above are subject to a number of unknowns including, but not limited to, that significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Ebola virus, comments and additional testing requested by the FDA if and when the Company files the Investigational New Drug application and whether the Company will be able to obtain a Tropical Disease Priority Review Voucher for the new drug application. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Two of the authors of the manuscript are officers or directors of the Company. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Investor Relations Contact
Jenene Thomas

GlobeNewswire Distribution ID 8789385

Play Ball! Major League Baseball and Zoom Announce First-of-its-kind Partnership; Zoom Contact Center to Power ‘Zoom Replay Operations Center’

  • Zoom becomes Official Unified Communications Platform of MLB and Presenting Partner of MLB Replay Review
  • MLB to introduce league-first, broadcast look-ins from the Zoom Replay Operations Center
  • Zoom Contact Center, Zoom Events, and Zoom’s all-in-one collaboration platform will deliver unprecedented transparency to the fans and enhanced communications between front office staff, umpires, and league officials

SAN JOSE, Calif. and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) — Major League Baseball (MLB) and Zoom Video Communications, Inc. (NASDAQ: ZM) today announced a first-of-its-kind partnership for the league, aimed to enhance MLB games and the fan viewership experience. As the new Official Unified Communications Platform of MLB, Zoom Contact Center and the Zoom platform technology will power new elements of Major League games and broadcasts.

MLB Chief Operations & Strategy Officer Chris Marinak, said: “We are always looking for innovative ways to leverage best-in-class technology to advance the MLB experience and deliver more to our fans. Partnering with Zoom, a category leader that reinvented the way we connect, was a natural next step for us. We are excited to integrate Zoom Contact Center and other Zoom platform technology into our gameday operations and continue to modernize experiences in a secure, reliable, and innovative way.”

Zoom Chief Marketing Officer, Janine Pelosi said: “MLB brings together tens of millions of passionate fans every season. Zoom’s rapid pace of innovation and obsession with making human connection easier and better, is crucial to help MLB evolve its experience and deliver unprecedented transparency and access to its fans. With MLB leveraging Zoom Contact Center and Zoom’s all-in-one collaboration platform, we are able to truly show the world how a historical brand can continue to innovate and unlock new possibilities.”

Zoom platform integration drives MLB innovations:

  • Zoom Contact Center transforms replay review – In the 2022 MLB season, there were more than 1,400 replay reviews. Historically, the league’s replay review was reliant on disparate technology and audio-only communication with umpires on the field, resulting in fans being disconnected from the decision-making process.

    Beginning with the 2023 Season, the Crew Chief, the most senior member of the four-man umpire crew, will connect to the Zoom Replay Operations Center using Zoom’s Contact Center solution during any replay review. During national broadcasts on MLB Network and Apple TV+, fans will also see the Zoom Replay Operations Center in action live during replay reviews and hear from an expert rules analyst who will discuss replay reviews with the broadcast team. MLB’s goal with this new setup is to create a more transparent and engaging review process.

  • Zoom Platform helps streamline communication – Zoom will be used to securely deliver sensitive information in one of the most high-pressure and high-profile MLB Events, Day One of the 2023 MLB Draft.
  • Broader league-wide Zoom integrations advance collaboration – Zoom’s all-in-one collaboration platform is integrated across several MLB clubs, platforms, and broadcast outlets. In addition to Zoom Meetings, many MLB teams are using Zoom Phone to stay connected with colleagues and customers, as well as Zoom Contact Center to deliver prompt, accurate, and highly personalized customer experiences to their fans. MLB’s corporate offices use Zoom Meetings, Zoom Rooms, Zoom Phone, and Zoom Webinar to connect, collaborate, and communicate.

To learn more about the Zoom platform and the technology that will power several new elements in MLB starting in the 2023 season, read the blog here.

About MLB
Major League Baseball (MLB) is the most historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Led by Commissioner Robert D. Manfred, Jr., MLB remains committed to making an impact in the communities of the U.S., Canada and throughout the world, perpetuating the sport’s larger role in society and permeating every facet of baseball’s business, marketing, community relations and social responsibility endeavors. MLB currently features record levels of competitive balance, continues to expand its global reach through programming and content to fans all over the world, and registered records in games and minutes watched this season on MLB.TV. With the continued success of MLB Network and MLB digital platforms, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. For more information on Major League Baseball, visit

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at

MLB Communications
David Hochman

Zoom Public Relations
Candace Dean

GlobeNewswire Distribution ID 8789553